- Health & Pharmaceuticals›
- Pharmaceutical Products & Market›
Savings through generic drug usage in the U.S., by age group 2017
Premium statistics
Industry-specific and extensively researched technical data (partially from exclusive partnerships).
A paid subscription is required for full access.
Savings through generic drug usage in the U.S., by age group 2017
Savings through generic drug usage in the United States in 2017, by age group (in billion U.S. dollars)
by Matej Mikulic,
last edited
Jul 17, 2018
This statistic depicts savings through generic drug usage in the United States in 2017, by age group. In that year, some 93 billion U.S. dollars were saved with generic products through people aged over 65 years.
Savings through generic drug usage in the United States in 2017, by age group (in billion U.S. dollars)
| Age group | Savings in billion U.S. dollars |
|---|---|
| - | - |
| - | - |
| - | - |
| - | - |
| Age group | Savings in billion U.S. dollars |
|---|---|
| - | - |
| - | - |
| - | - |
| - | - |
Exclusive Premium statistic
You need a Premium Account for unlimited access.
Full access to 1m statistics
Incl. source references
Available to download in PNG, PDF, XLS format
Premium Account
only $49 / month
*
Exclusive content
Exclusive Premium statistic
You need a Premium Account for unlimited access.
Full access to 1m statistics
Incl. source references
Available to download in PNG, PDF, XLS format
Premium Account
only $49 / month
*
© Statista 2019
About this statistic
Show source
Download
Settings
Share
Chart type
Datalabels
Share on Social Media
Download started
Please be patient - this may take a moment
Please be patient - this may take a moment
Description
Source
More information
by Matej Mikulic,
last edited
Jul 17, 2018
This statistic depicts savings through generic drug usage in the United States in 2017, by age group. In that year, some 93 billion U.S. dollars were saved with generic products through people aged over 65 years.
- Show sources information
- Show publisher information
- Release date
- July 2018
- Region
- United States
- Survey time period
- 2017
- Supplementary notes
- All figures are rounded. Figures are calculated based on given percentages.
Source
- Show sources information
- Show publisher information
- Release date
- July 2018
More information
- Region
- United States
- Survey time period
- 2017
- Supplementary notes
- All figures are rounded. Figures are calculated based on given percentages.
Other statistics on the topic
+Pharmaceutical Products & Market
Pharmaceutical market: worldwide revenue 2001-2018
+Pharmaceutical Products & Market
Revenues of leading global generics manufacturers 2018
+Pharmaceutical Products & Market
U.S. brand and generic prescription drug revenue 2005-2018
+Pharmaceutical Products & Market
Pfizer's revenue by segment 2014-2018
Statista Accounts:
Access All Statistics. Starting from $588 / Year
Basic Account
Get to know the platform
You only have access to basic statistics.
This statistic is not included in your account!
Premium Account
Your perfect start with Statista
- Instant access to 1m statistics
- Download in XLS, PDF & PNG format
- Detailed references
$49 / Month *
Corporate Account
Full access
Corporate solution including all features.
* All products require an annual contract.
Prices do not include sales tax.
Prices do not include sales tax.
Leading companies trust Statista:
Related Studies: Available to Download in PDF or PPTX Format
All Information
in one Presentation
Generics and biosimilars
- 86 page/s
- English
- pptx
- Detailed references
Everything On "Generics and biosimilars" in One Document: Edited and Divided into Handy Chapters. Including Detailed References.
Statista is a great source of knowledge, and pretty helpful to manage the daily work.Christof Baron
CEO, MindShare Germany
Statistics on "Generics and biosimilars"
- Global overview
The most important statistics
- Revenue of the worldwide pharmaceutical market from 2001 to 2018 (in billion U.S. dollars)Pharmaceutical market: worldwide revenue 2001-2018
- Worldwide total generic prescription drug revenue from 2010 to 2024 (in billion U.S. dollars)Total worldwide generic prescription drug revenue 2010-2024
- Worldwide generic prescription drug revenue as a percent of total prescribed revenue from 2010 to 2024Global generic prescription drug revenues as share of prescribed revenue 2010-2024
- Worldwide total prescription drug revenue at risk from patent expiration from 2010 to 2024 (in billion U.S. dollars)*Patent expiration risks for total worldwide prescription drug revenue 2010-2024
- Top companies
The most important statistics
- Top generics manufacturers based on revenue in 2018 (in billion U.S. dollars)*Revenues of leading global generics manufacturers 2018
- Generic revenues of Teva Pharmaceutical Industries from 2016 to 2018, by region (in million U.S. dollars)Teva Pharmaceutical Industries' generic revenues by region 2016-2018
- Novartis AG's revenue from 2014 to 2018, by segment (in billion U.S. dollars)Novartis revenue 2014-2018 by segment
- Pfizer's revenue in 2014 and 2018, by segment (in million U.S. dollars)*Pfizer's revenue by segment 2014-2018
- U.S. market
The most important statistics
- Brand and generic prescription medication revenue in the U.S. from 2006 to 2018 (in billion U.S. dollars)*Brand and generic prescription medication revenue in the U.S. 2006-2018
- Proportion of branded versus generic prescription drug revenues in the United States from 2005 to 2018U.S. brand and generic prescription drug revenue 2005-2018
- Change in branded and generic medication spending in the United States from 2013 to 2018 (in billion U.S. dollars)*Spending change on branded and generic medicines in the U.S. 2013-2018
- Top generic drug companies by unbranded generics revenue in the U.S. in 2016-2017 (in billion U.S. dollars)*Unbranded generics revenue top corporations in U.S. 2016-2017
- Top companies based on unbranded generics U.S. market share during 2016-2017*Unbranded generics market share top corporations in U.S. 2016-2017
- Top 20 U.S. pharma products by dispensed prescriptions in 2018 (in millions)Top U.S. pharma products by prescriptions 2018
- Patent expiration
The most important statistics
- Small molecules sales at risk due to patent expirations in the U.S. from 2009 to 2022 (in billion U.S. dollars)Projected sales at risk due to patent expiry 2009-2022
- Leading pharmaceutical companies based on sales loss due to patent risk until year-end 2018Top pharma companies by sales loss due to patent loss until 2018
- Forecast of new brand and brand loss of exclusivity (LOE) impact on growth in developed pharmaceutical markets from 2018 to 2022 (in billion U.S. dollars)*Forecast of new brand and LOE impact on growth of developed pharma markets 2018-2022
- Selected top branded biologic drugs in the United States that will go generic between 2016 and 2028, by revenue (in billion U.S. dollars)*Top branded biologic drugs in the U.S. that will go generic by 2028
- Time from launching a brand drug to meeting a paragraph IV patent challenge in the U.S. from 1995 to 2014Time from brand drug launch to generic patent challenges U.S. 1995-2014
- Comparison of brand pre-expiry price and generic price of selected drugs in the United States as of 2015 (in U.S. dollars)Comparison of pre-expiry and generic price for drugs U.S. 2015
- Savings
The most important statistics
- Savings through generic drug usage in the United States from 2008 to 2018 (in billion U.S. dollars)Savings through generic drug usage in the U.S. 2008-2018
- Top generic drugs based on savings in the United States in 2017 (in million U.S. dollars)Total savings of top generic drugs in U.S. 2017
- Cost savings through generics in the United States in 2017, by therapeutic area (in billion U.S. dollars)*Saving of U.S. costs through generic pharmaceuticals by therapy 2017
- Savings through generic drug usage in the United States in 2017, by age group (in billion U.S. dollars)Savings through generic drug usage in the U.S., by age group 2017
- Savings through generic drug usage in the United States in 2017, by payer (in billion U.S. dollars)Savings through generic drug usage in the U.S., by payer 2017
- Percentage of savings through generic drug usage in the United States in 2017, by payerPercentage savings through generic drug usage in the U.S. by payer 2017
- Percentage of savings through generic drug usage in the United States in 2017, by age groupSavings through generic drug usage in the U.S., by age group share 2017
- Biosimilars
The most important statistics
- Cumulative potential biosimilars market in EU-5 countries and the U.S. between 2016 and 2020 (in billion euros)Cumulative potential biosimilars market in EU5 countries and the U.S. 2016-2020
- Number of biosimilars in development worldwide as of October 2017, by country Country-wise biosimilar pipelines number in development worldwide 2017
- Projected reduction in U.S. biosimilar direct spending on originator biologics as of 2018 (in billion U.S. dollars)Reduction in U.S. direct spending on originator biologics as of 2018
- Filgrastim market share of Neupogen and its U.S. biosimilar competitors from 2015 to 2017Share of filgrastim sales attributable to Neupogen or biosimilars US 2015-2017
- Insulin glargine market share of Lantus and its U.S. biosimilar competitor from 2015 to 2017Share of insuline glargine sales Lantus vs. biosimilar US 2015-2017
- Percentage of U.S. health care executives who foresee biosimilars reducing drug spend for specialty drugs in 2017-2020*Opinion on drug spending reduction due to biosimilars for specialty drugs 2017-2020
- Example of physician office payment for biosimilars in Medicare Part B as of 2019 (in U.S. dollars)*Physician office payment for biosimilars in Medicare Part B in 2019
Discover Statista
Need help with using Statista for your research?
Tutorials and first steps
Further Content: Statistics, Studies, and Topic Pages
Statistics
- Medicaid program savings through generic drug usage by U.S. state 2015
- Medicare savings through generic drug usage in the U.S. by state 2015
- Top generic entry drug savings in Canada by public drug plan 2012/2013
- Share of generic drugs in the pharmaceutical market in France 2016
- Generic substitution savings in France 2007-2014
- Generic market share value change worldwide 2006 vs. 2016, by region
- Generic market share change in unit volume worldwide 2006 vs. 2016, by region
- Generic share of dispensed prescriptions by formulation U.S. 2012 vs. 2017
- Spending on dispensed total vs. generic prescriptions in the U.S. 2017
- Share of top generic purchasing operations in U.S. 2017
- Adjusted and unadjusted generic prescription growth in U.S. 2013-2017
- U.S. total vs. generic dispensed prescription numbers 2017, by formulation
- Generic drug cost change for Canada 2016-2018
- Annual growth of the global generic market 2009-2015 by region
- Price difference of a patented drug vs. its generic in selected countries 2010
- Gross savings in Bhutan 2006-2017
- Italy: willingness to make sacrifices to retire early 2015
- Gross savings in Vietnam 2005-2017
- Gross savings as a share of GDP in Bhutan 2006-2017
- Italy: prevalence of generic beta blocker use 2006-2016
Studies
- Generics and biosimilars in Italy
- Generics and biosimilars
- 2018 Generic Drug Access & Savings in the United States
- 2017 Generic Drug Access & Savings in the United States
- Generic Drug Savings in the U.S. 2014
- Generic Drug Savings in the U.S. 2015
- 2016 Generic Drug Savings & Access Report in the United States
- Global Generic and Biosimilars Trends and Insights
- U.S. pharmaceutical industry
- Generic Drugs in Canada, 2016
- Canadian pharmaceutical industry
- Pharmaceutical industry in Mexico
- Teva
- Pharmaceutical industry in India
- AAM - 2017 Annual Report
Statistics on "Generics and biosimilars"
- Revenue of the worldwide pharmaceutical market from 2001 to 2018 (in billion U.S. dollars)
- Worldwide total generic prescription drug revenue from 2010 to 2024 (in billion U.S. dollars)
- Worldwide generic prescription drug revenue as a percent of total prescribed revenue from 2010 to 2024
- Worldwide total prescription drug revenue at risk from patent expiration from 2010 to 2024 (in billion U.S. dollars)*
- Top generics manufacturers based on revenue in 2018 (in billion U.S. dollars)*
- Generic revenues of Teva Pharmaceutical Industries from 2016 to 2018, by region (in million U.S. dollars)
- Novartis AG's revenue from 2014 to 2018, by segment (in billion U.S. dollars)
- Pfizer's revenue in 2014 and 2018, by segment (in million U.S. dollars)*
- Brand and generic prescription medication revenue in the U.S. from 2006 to 2018 (in billion U.S. dollars)*
- Proportion of branded versus generic prescription drug revenues in the United States from 2005 to 2018
- Change in branded and generic medication spending in the United States from 2013 to 2018 (in billion U.S. dollars)*
- Top generic drug companies by unbranded generics revenue in the U.S. in 2016-2017 (in billion U.S. dollars)*
- Top companies based on unbranded generics U.S. market share during 2016-2017*
- Top 20 U.S. pharma products by dispensed prescriptions in 2018 (in millions)
- Small molecules sales at risk due to patent expirations in the U.S. from 2009 to 2022 (in billion U.S. dollars)
- Leading pharmaceutical companies based on sales loss due to patent risk until year-end 2018
- Forecast of new brand and brand loss of exclusivity (LOE) impact on growth in developed pharmaceutical markets from 2018 to 2022 (in billion U.S. dollars)*
- Selected top branded biologic drugs in the United States that will go generic between 2016 and 2028, by revenue (in billion U.S. dollars)*
- Time from launching a brand drug to meeting a paragraph IV patent challenge in the U.S. from 1995 to 2014
- Comparison of brand pre-expiry price and generic price of selected drugs in the United States as of 2015 (in U.S. dollars)
- Savings through generic drug usage in the United States from 2008 to 2018 (in billion U.S. dollars)
- Top generic drugs based on savings in the United States in 2017 (in million U.S. dollars)
- Cost savings through generics in the United States in 2017, by therapeutic area (in billion U.S. dollars)*
- Savings through generic drug usage in the United States in 2017, by age group (in billion U.S. dollars)
- Savings through generic drug usage in the United States in 2017, by payer (in billion U.S. dollars)
- Percentage of savings through generic drug usage in the United States in 2017, by payer
- Percentage of savings through generic drug usage in the United States in 2017, by age group
- Cumulative potential biosimilars market in EU-5 countries and the U.S. between 2016 and 2020 (in billion euros)
- Number of biosimilars in development worldwide as of October 2017, by country
- Projected reduction in U.S. biosimilar direct spending on originator biologics as of 2018 (in billion U.S. dollars)
- Filgrastim market share of Neupogen and its U.S. biosimilar competitors from 2015 to 2017
- Insulin glargine market share of Lantus and its U.S. biosimilar competitor from 2015 to 2017
- Percentage of U.S. health care executives who foresee biosimilars reducing drug spend for specialty drugs in 2017-2020*
- Example of physician office payment for biosimilars in Medicare Part B as of 2019 (in U.S. dollars)*
- Savings through generic drug usage in Medicaid during 2015, by state (in million U.S. dollars)
- Savings through generic drug usage in Medicare during 2015, by state (in million U.S. dollars)*
- Savings for top 5 generic entry drugs in select Canadian drug plans in 2012/2013 (in 1,000 Canadian dollars)
- Distribution of generic drugs in the French pharmaceutical market in 2016, according to value and volume
- Annual amounts saved thanks to generic substitution in France from 2007 to 2014* (in million euros)
- Change in the value of generics market share worldwide between 2006 and 2016, by region
- Change in the unit volume of generics market share worldwide between 2006 and 2016, by region*
- Percentage of U.S. dispensed prescriptions that were generics in 2012 and 2017, by formulation
- Spending on dispensed total vs. generics prescriptions in the U.S. in 2017, by formulation (in billion U.S. dollars)
- Distribution of top generic purchasing operations in the U.S. in 2017
- Adjusted and unadjusted generics prescription volume growth in the U.S. from 2013 to 2017
- Number of dispensed total vs. generics prescriptions in the U.S. in 2017, by formulation (in millions)
- Generic drug cost growth for Canada from 2016 to 2018
- Average annual growth of the global generic market 2009-2015, by region
- Average price difference of a patented drug vs. its generic in selected countries in 2010
- Gross savings in Bhutan from 2006 to 2017 (in million U.S. dollars)
- Would you be willing to make sacrifices to retire early?
- Gross savings in Vietnam from 2005 to 2017 (in billion U.S. dollars)
- Gross savings as a share of GDP in Bhutan from 2006 to 2017
- Share of individuals taking generic beta blockers* in Italy from 2006 to 2016
Statista Accounts:
Access All Statistics. Starting from $588 / Year
Related topics
About Statista
Statista offers dossiers and reports on over 170 industries. With Statista you are always able to make informed decisions and boost your work efficiency.
Internet & Telecommunications
- Social Media
- E-Commerce
- Online Video & Entertainment
- Advertising & Marketing
Consumer Goods & FMCG
- Alcoholic Beverages
- Cleaning Products
- Cosmetics & Personal Care
- Food & Nutrition
Retail & Trade
- Health & Hygiene
- International Trade
- Shopping Behavior
- Sports & Leisure
Travel, Tourism & Hospitality
- Business Travel
- Leisure Travel
- Accomodation
- Restaurants
Society
- Demographics
- Economy
- Education & Science
- Politics & Government
Transportation & Logistics
- Aviation
- Rail Transport
- Vehicles & Road Traffic
- Water Transport
Save statistic in .XLS format
You can only download this statistic as a Premium user.
Save statistic in .PNG format
You can only download this statistic as a Premium user.
Save statistic in .PDF format
You can only download this statistic as a Premium user.
Show source references
As a Premium user you get access to the detailed source references and background information about this statistic.
Show details about this statistic
As a Premium user you get access to background information and details about the release of this statistic.
Bookmark statistics
As soon as this statistic is updated, you will immediately be notified via e-mail.
Change statistics options
You need at least a Premium Account to use this feature.
Exclusive Corporate feature
This feature is limited to our corporate solutions.
Please contact us to get started with full access to dossiers, forecasts, studies and international data.
Corporate Account
We use cookies to personalize contents and ads, offer social media features, and analyze access to our website. In your browser settings you can configure or disable this, respectively, and can delete any already placed cookies. For details, please see your browser’s Help section (by pressing F1). Please see our privacy statement for details about how we use data.